EcoDrugPlus

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSBSLG00000003547
Gene Symbol: LOC114850796
3 Cross references
203 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSBSLG00000001797
Gene Symbol: LOC114862999
3 Cross references
202 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSBSLG00000008452
Gene Symbol: LOC114867247
3 Cross references
202 Possible Orthologues:

Prostaglandin F Receptor

Ensembl ID : ENSBSLG00000012499
Gene Symbol: PTGFR
3 Cross references
195 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSBSLG00000007204
Gene Symbol: PTGIR
3 Cross references
188 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSBSLG00000016014
Gene Symbol: PTGS1
3 Cross references
196 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSBSLG00000013422
Gene Symbol: PTGS1
3 Cross references
196 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2

Ensembl ID : ENSBSLG00000022926
Gene Symbol: PTGS2
3 Cross references
213 Possible Orthologues:

Proteasomal Ubiquitin Receptor Adrm1-Like

Ensembl ID : ENSBSLG00000021279
Gene Symbol: LOC114858420
3 Cross references
197 Possible Orthologues:

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSBSLG00000019724
Gene Symbol: PSMA1
3 Cross references
271 Possible Orthologues:

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSBSLG00000026492
Gene Symbol: PSMA2
3 Cross references
278 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSBSLG00000009358
Gene Symbol: PSMA3
3 Cross references
252 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).